Fig. 9
From: Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment
SI-2 treatment and SRC-3 KD do not suppress breast tumor growth in immune-deficient female mice. A Luciferase activity in E0771 breast tumors from C57BL/6J-SCID mice treated with SI-2 (2.5Â mg/kg) or vehicle. B Quantification of luciferase activity in the E0771 breast tumors in Panel A is shown in the graph. C Luciferase activity in E0771 tumors from C57BL/6J-SCID mice treated with SI-2 (10Â mg/kg) or vehicle. D Quantification of luciferase activity in the E0771 breast tumors in Panel C is shown in the graph. E 4T1 breast tumor luciferase activity in SCID mice treated with SI-2 (2.5Â mg/kg) or vehicle. F Quantification of 4T1 breast tumor luciferase activity in Panel E is shown in the graph. G Luciferase activity in SRC-3 KD E0771 versus control KD E0771 breast tumors in SCID mice. H Quantification of luciferase activity in the SRC-3 KD E0771 versus control KD E0771 breast tumors in Panel G is shown in the graph. I Luciferase activity of SRC-3 KD versus control KD 4T1 breast tumors in SCID mice. J Quantification of the luciferase activity of SRC-3 KD versus control KD 4T1 cells in Panel I is shown in the graph. DTD, Drug Treatment Days. N.S., Non Specific